Investigational Drug Information for BIIB021
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug BIIB021?
BIIB021 is an investigational drug.
There have been 7 clinical trials for BIIB021.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2009.
The most common disease conditions in clinical trials are Neoplasms, Breast Neoplasms, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are Biogen and [disabled in preview].
Summary for BIIB021
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 551 |
WIPO Patent Applications | 327 |
Japanese Patent Applications | 226 |
Clinical Trial Progress | Phase 2 (2009-11-01) |
Vendors | 91 |
Recent Clinical Trials for BIIB021
Title | Sponsor | Phase |
---|---|---|
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding | Biogen | Phase 2 |
Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors | Biogen | Phase 1 |
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) | Biogen | Phase 2 |
Clinical Trial Summary for BIIB021
Top disease conditions for BIIB021
Top clinical trial sponsors for BIIB021
US Patents for BIIB021
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |